NCT00219284 - Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease | Biotech Hunter

Enrollment

359

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Parkinson's Disease With End of Dose Wearing Off

Interventions

DRUG

Carbidopa/levodopa/entacapone

Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.

Trial Locations (42)

11725

Commack

18301

East Stroudsburg

20007

Washington D.C.

21201

Baltimore

27607

Raleigh

27705

Durham

33021

Hollywood

33060

Pompano Beach

33308

Fort Lauderdale

33324

Plantation

33418

Palm Beach

33486

Boca Raton

33952

Port Charlotte

34102

Naples

34205

Bradenton

39401

Hattiesburg

44718

Canton

44811

Bellevue

48025

Bingham Farms

48034

Southfield

53233

Milwaukee

60402

Flossmoor

60637

Chicago

63141

St Louis

65201

Columbia

66214

Lenexa

66606

Topeka

77030

Houston

80524

Fort Collins

85006

Phoenix

90033

Los Angeles

91105

Pasadena

91355

Reseda

92037

La Jolla

92618

Irvine

92835

Fullerton

94305

Stanford

97602

Tualatin

98405

Tacoma

99204

Spokane

07450

Ridgewood

00983

Caroline